Ferri C, Bernini L, Bombardieri S, Pasero G
Scand J Rheumatol. 1986;15(4):356-62. doi: 10.3109/03009748609098203.
Thirty-three patients with progressive systemic sclerosis (PSS) (24 women and 9 men, 27 with diffuse scleroderma and 6 with CREST syndrome) were treated with griseofulvin alone (375-500 mg/day) for 12-84 months (mean 33). Clinical and functional assessment of the results included: a self-evaluation (general status, skin toughness, cold sensitivity, dysphagia), a physical examination (fingerprint areas, chest expansion, mouth widening, grip strength) routine laboratory tests, electrocardiogram, glomerular filtration rate (GFR), esophagus and chest X-rays. After griseofulvin, a significant improvement was noted in 28/33 patients (85%) regarding subjective condition and skin thickening and elasticity, particularly in the trunk and proximal limbs (p less than 0.05 for chest expansion), and of GFR (p less than 0.01). Lung and esophageal involvement, on the whole, remained unchanged during the treatment, which does not appear to modify the progression of PSS myocardiopathy. No patient stopped using griseofulvin because of side effects. The present results show that griseofulvin is a safe drug for PSS treatment and that it can influence the skin and renal involvement.
33例进行性系统性硬化症（PSS）患者（24例女性，9例男性，27例弥漫性硬皮病，6例CREST综合征）单独使用灰黄霉素（375 - 500毫克/天）治疗12 - 84个月（平均33个月）。对结果的临床和功能评估包括：自我评估（一般状况、皮肤韧性、冷敏感性、吞咽困难）、体格检查（指纹区域、胸廓扩张度、张口度、握力）、常规实验室检查、心电图、肾小球滤过率（GFR）、食管和胸部X线检查。使用灰黄霉素治疗后，28/33例患者（85%）在主观状况、皮肤增厚及弹性方面有显著改善，尤其是在躯干和近端肢体（胸廓扩张度p < 0.05），GFR也有改善（p < 0.01）。总体而言，治疗期间肺部和食管受累情况保持不变，治疗似乎并未改变PSS心肌病的进展。没有患者因副作用而停止使用灰黄霉素。目前的结果表明，灰黄霉素是治疗PSS的一种安全药物，并且可以影响皮肤和肾脏受累情况。
